Pathfinder Cell Therapy Stock Fundamentals
| PFND Stock | USD 0.0001 0.00 0.00% |
Pathfinder Cell Therapy fundamentals help investors to digest information that contributes to Pathfinder Cell's financial success or failures. It also enables traders to predict the movement of Pathfinder Pink Sheet. The fundamental analysis module provides a way to measure Pathfinder Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pathfinder Cell pink sheet.
Pathfinder |
Pathfinder Cell Therapy Company Return On Asset Analysis
Pathfinder Cell's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Pathfinder Cell Return On Asset | -8.89 |
Most of Pathfinder Cell's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pathfinder Cell Therapy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Pathfinder Cell Therapy has a Return On Asset of -8.8876. This indicator is about the same for the Biotechnology average (which is currently at -8.75) sector and 62.34% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Pathfinder Cell Therapy Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pathfinder Cell's current stock value. Our valuation model uses many indicators to compare Pathfinder Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pathfinder Cell competition to find correlations between indicators driving Pathfinder Cell's intrinsic value. More Info.Pathfinder Cell Therapy is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pathfinder Cell's earnings, one of the primary drivers of an investment's value.Pathfinder Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pathfinder Cell's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pathfinder Cell could also be used in its relative valuation, which is a method of valuing Pathfinder Cell by comparing valuation metrics of similar companies.Pathfinder Cell is currently under evaluation in return on asset category among its peers.
Pathfinder Fundamentals
| Return On Asset | -8.89 | |||
| Current Valuation | 7.41 M | |||
| Shares Outstanding | 667.16 M | |||
| EBITDA | (1.67 M) | |||
| Net Income | (1.39 M) | |||
| Cash And Equivalents | 4 K | |||
| Total Debt | 5.41 M | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (963 K) | |||
| Beta | 0.14 | |||
| Market Capitalization | 2 M | |||
| Total Asset | 106 K | |||
| Retained Earnings | (19.23 M) | |||
| Working Capital | (6.76 M) | |||
| Current Asset | 9 K | |||
| Current Liabilities | 6.77 M | |||
| Net Asset | 106 K |
About Pathfinder Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pathfinder Cell Therapy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pathfinder Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pathfinder Cell Therapy based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. PATHFINDER CELL operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 1 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in Pathfinder Pink Sheet
Pathfinder Cell financial ratios help investors to determine whether Pathfinder Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pathfinder with respect to the benefits of owning Pathfinder Cell security.